ClinicalTrials.gg
CompletedNCT01350609Updated Dec 10, 2015

Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed

A Phase 1 interventional study of Nifedipine/Candesartan (BAY 98-7106) and Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333) in Hypertension, Essential, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-10.

Sponsored by Bayer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Essential Hypertension with a site in Germany — 1 open to participants now, 3 under way, none of them phase 3. Essential Hypertension · Germany.

Enrollment
33rd of 35
49 · median 429
Started
2011
with 1 other
Phase 1
2 of 35
none open now
Registered
26th of 35
by date
Lead sponsor
2 of 35
Bayer

Among the 35 studies in Essential Hypertension with a site in Germany, this one is the 33rd largest by enrollment, is one of 2 that started in 2011, is one of 2 in phase 1, and was the 26th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 35 studies in Essential Hypertension with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Essential Hypertension with a site in Germany, or all of them as a file.
02

Study summary

Randomized, open label, single dose, 2-way crossover study to investigate the bioequivalence of a new fixed dose combination (FDC) tablet of nifedipine GITS and candesartan with the corresponding loose combination under fed conditions.

Read the detailed description

Clinical pharmacology

03

Conditions studied

  • Hypertension, Essential

Keywords

  • essential hypertension, blood pressure, nifedipine, candesartan, FDC
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The form must be signed before any study specific tests or procedures are done
  • Confirmation of the subject's health insurance coverage prior to the first screening visit
  • Healthy male subject
  • Ethnicity: Caucasian
  • Age: 18 to 45 years (inclusive) at the first screening visit
  • (BMI) above or equal 18, and below or equal 29.9 kg / m²
  • Ability to understand and follow study-related instructions

Exclusion criteria

Exclusion Criteria:

  • Suspicion of drug or alcohol abuse
  • Regular daily consumption of more than 1 L of xanthin-containing beverages
  • Intake of foods or beverages containing grapefruit within 2 weeks prior to the first study drug administration (the same applies to pomelos and St. John's Wort)
  • Use of medication within 4 weeks prior to the first study drug administration which could interfere with the products (e.g. inhibitors or CYP3A inducers)

    • examples for CYP3A inhibitors: erythromycin, inhibitors of human protease (e.g. ritonavir, saquinavir), amiodarone, diltiazem, verapamil, fluconazole, itraconazole, ketoconazole, clarithromycin, telithromycin, nefazodon, cimetidine;
    • examples for CYP3A inducers: rifampicin, carbamazepin, phenytoin, phenobarbital, or products containing St. John's Wort;
  • Systolic blood pressure below 116 or above 145 mmHg (after at least 15 min supine)
  • At the first screening visit

    • Diastolic blood pressure above 95 mmHg (after at least 15 min supine)
    • Heart rate below 45 or above 95 beats / min (after at least 15 min supine) at the first screening visit
    • findings in the physical examination
    • Positive urine drug screening or alcohol breath test
  • Exclusion periods from other studies or simultaneous participation in other clinical studies
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Nifedipine/Candesartan (fixed dose)

    Drug: Nifedipine/Candesartan (BAY 98-7106)

  • Active comparator
    Nifedipine/Candesartan (loose)

    Drug: Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)

Interventions

  • DrugNifedipine/Candesartan (BAY 98-7106)

    Drug pages: Nifedipine · Candesartan

    Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)

  • DrugNifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)

    Drug pages: Nifedipine · Candesartan

    Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum drug concentration in plasma after dose administration for nifedipine and candesartan

    Time frame: within 48 hours after each dosing

  2. AUC(0-tlast)

    Area under the drug-concentration vs. time curve from time 0 to the last data point for nifedipine and candesartan

    Time frame: within 48 hours after each dosing

Secondary outcomes

  1. AUC

    Area under the curve from time 0 to infinity after single dose for nifedipine and candesartan

    Time frame: Within 48 hours after each dosing

  2. Cmax,norm

    Dose normalized Cmax for nifedipine and candesartan

    Time frame: Within 48 hours after each dosing

  3. AUCnorm

    AUC normalized for dose and body weight for nifedipine and candesartan

    Time frame: Within 48 hours after each dosing

  4. AUC(0-48)

    Area under the plasma concentration-time curve from time zero to 48h for nifedipine and candesartan

    Time frame: Within 48 hours after each dosing

  5. Tmax

    The time of the maximum concentration for nifedipine and candesartan

    Time frame: Within 48 hours after each dosing

  6. t1/2

    Half-life for nifedipine and candesartan

    Time frame: Within 48 hours after each dosing

  7. MRT

    The mean residence time for nifedipine and candesartan

    Time frame: Within 48 hours after each dosing

  8. CL/F

    Oral plasma clearances for nifedipine and candesartan

    Time frame: Within 48 hours after each dosing

  9. Number of participants with adverse events

    Time frame: Approximately 3-7 weeks per subject

07

Study locations

1 site
  • Berlin, 13353, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Aug 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2011
First posted
May 10, 2011
Start
Apr 2011
Primary completionActual
Aug 2011
CompletionActual
Sep 2011
Last update
Dec 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01350609
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 10, 2011
Start date
Apr 2011
Primary completion
Aug 2011
Completion
Sep 2011
Last update
Dec 10, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nifedipine · Candesartan

Start the discussion